Staphylococcal superantigen-like 10 inhibits cxcl12-lntlucetl human Tumor cell migration1 www.neoplasia.com

Neoplasia

Volumn 11, Issue 4, 2009, Pages 333-344

  Walenkamp, Annemiek M E ^a,b   Boer, Ingrid G J ^b   Bestebroer, Jovanka ^b   Rozeveld, Dennie ^a   Timmer Bosscha, Hetty ^a   Hemrika, Winger ^c   Van Strijp, Jos A G ^b   De Haas, Carla J C ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c U Protein Express BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CALCIUM; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1; SUPERANTIGEN; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING; ARTICLE; CALCIUM MOBILIZATION; CANCER CELL; CANCER CELL CULTURE; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOBLAST; TUMOR CELL; UTERINE CERVIX CARCINOMA; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; IMMUNOLOGY; METABOLISM; NEOPLASM; POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; HUMANS; NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; STAPHYLOCOCCUS; SUPERANTIGENS; TRANSFECTION;

EID: 65549112170     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81508     Document Type: Article

References (51)

1. Zlotnik A (2006). Chemokin. es and cancer. Int J Cancer 119, 2026-2029.
2. Ruffini PA, Morandi P Cabioglu N, Altundag K, and Cristofanî llî M (2007). Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109, 2392-2404.
3. Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4, 540-550.
4. Takeuchi H, Kitago M, and Hoon DS (2007). Effects of chemokines on tumor metastasis. Cancer Treat Res 135, 177-184.
5. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson. E, Piwnica-Worms D, and Luker GD (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64, 8604-8612.
6. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley LK (2002). Use of the stromal cell-derived factor-l/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-1837.
7. Zeelenberg IS, Ruuls-Van SL, and Roos E (2003). The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63, 3833-3839.
8. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvátore G, Faviana P, Basólo F, Santoro M, and Melillo RM (2007). Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thy- roid cancer. Cancer Res 67, 11821-11829.
9. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
10. Zhang JP, Lu WG, Ye F, Chen HZ, Zhou CY, and Xie X (2007). Study on CXCR4/SDF-1 alpha axis in lymph node metastasis of cervical squamous cell carcinoma. IntJ Gynecol Cancer 17, 478-483.
11. Burger JA and. Burkle A (2007). The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137, 288-296.
12. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, and Garcia-Pardo A (2006). MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4bet al. integrin or CXCR4 engagement via distinct sig- naling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108, 31.43-31.51.
13. Juarez J, Bradstock KF, Gottlieb DJ, and Bendall LJ (2003). Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17, 1294-1300. (Pubitemid 36857336)
14. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, and Burger JA (2005). Small peptide inhibitors of the CXC. R4 chemokine recep- tor (CDl 84) antagonize the activation, migration, and antiapoptotic responses of CXCLl 2 in chronic lymphocytic leukemia B cells. Blood 106, 1824-1830.
15. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, and Konopleva M (2006). Inhibition of CXCR4 with, the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. MoI Cancer Ther 5, 3113-3121. (Pubitemid 46092053)
16. Rombouts EJ, Pavic B, Lowenberg B, and Ploemacher RE (2004). Relation, be- tween CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104, 550-557. (Pubitemid 38900040)
17. Dialynas DP, Shao L, Billman GF, and Yu J (2001). Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection, of human cord blood. Stem Cells 19, 443-452.
18. Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, Mohle R, and Meister B (2001). High expression of the chemokine receptor CXCR4 predicts extramedullary organ Infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 115, 545-553.
19. Sinha G (2003). Bacterial battalions join war against cancer. Nat Med 9, 1229.
20. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van. Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, and van Strijp JA (2004). Chemotaxis inhibi- tory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp Med 199, 687-695.
21. Haas PJ, de Haas CJ, Kleibeuker W, Poppelier MJ, Van Kessel KP, Kruijtzer JA, Liskamp RM, and van Strijp JA (2004). N-terminal residues of the Chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J. Immunol 173, 5704-5711.
22. Postma B, Poppelier MJ, van Galen. JC, Prossnitz ER, van Strijp JA, de Haas CJ, and Van Kessel KP (2004). Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol 172, 6994-7001.
23. Postma B, Kleibeuker W, Poppelier MJ, Boonstra M, Van Kessel KP van Strijp JA, and de Haas CJ (2005). Residues 10-18 within the C5a receptor N terminus compose a binding domain for Chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 280, 2020-2027.
24. Haas PJ, de Haas CJ, Poppelier MJ, Van. Kessel KP van Strijp JA, Dijkstra K, Scheek RM, Fan H, Kruijtzer JA, Liskamp RM, et al. (2005). The structure of the C5a receptor-blocking domain of Chemotaxis inhibitory protein oí Staphylococcus aureus is related to a group of immune evasive molecules. JMoI Biol 353, 859-872.
25. Prat C, Bestebroer J, de Haas CJ, van Strijp JA, and. Van Kessel KP (2006). A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like I. JImmunol 177, 8017-8026.
26. Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim. RB, Van Wamel WJ, Van. Kessel KP, and van. Strijp JA (2005). Immune evasion by a staphylococcal complement inhibitor that acts on C3 conveitases. Nat Immunol 6, 920-927.
27. Rooijakkers SH, Milder FJ, Bardoel BW, Ruyken M, van Strijp JA, and Gros P (2007). Staphylococcal complement inhibitor: structure and active sites. JImmunol 179, 2989-2998.
28. Durocher Y, Perret S, and Kamen A (2002). High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30, E9.
29. Bestebroer J, Poppelier MJ, Ulfman LH, Lenting PJ, Denis CV, Van Kessel KP, van Strijp JA, and de Haas CJ (2007). Staphylococcal superantigen-like 5 binds PSGL-I and inhibits P-sdectin-mediated neutrophil rolling. Blood 109, 2936-2943.
30. Chung MC, Wines BD, Baker H, Langley RJ, Baker EN, and Fraser JD (2007). The crystal structure of staphylococcal, superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibi- tion. MoI Microbiol 66, 1342-1355.
31. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfbld ME, Sunshine MJ, Littman DR Kuo CJ, et al. (2006). A novel chemokine re- ceptor for SDF-I and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp AW 203, 2201-2213.
32. Paul R, Remes K, LakkalaT, and Pelliniemi TT (1994). Spontaneous remission in acute myeloid leukaemia. Br J Haematol 86, 210-212.
33. Maywald O, Buchheidt D, Bergmann J, Schoch C, Ludwig WD, Reiter A, Hastka J, Lengfdder E, and Hehlmann R (2004). Spontaneous remission in adult acute myeloid leukemia in. association with, systemic bacterial, infection--case re- port and review of the literature. Ann Hematol6i, 189-194.
34. Fitzgerald JR, Reid SD, Ruotsalainen E, Tripp TJ, Liu M, Cole R, Kuusela P Schlievert PM, Jarvinen A, and Musser JM (2003). Genome diversification in Staphylococcus aureus: molecular evolution of a highly variable chromosomal re- gion encoding the staphylococcal exotoxin-like family of proteins. Infect Immun 71, 2827-2838.
35. Jongerius I, Kohl J, Pandey MK, Ruyken M, Van Kessel KP, van Strijp JA, and Rooijakkers SH (2007). Staphylococcal complement evasion by various convertase- blocking molecules. J. Exp Med 204, 2461-2471.
36. Langley R, Wines B, Willoughby N, Basu I, Proft T, and Fraser JD (2005). The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J. Immunol 174, 2926-2933.
37. Ui M (1990). ADP-Ribosylating Toxins and G Proteins. Washington, DC: American Society for Microbiology, 64.
38. Rahimpour R, Mitchell G, Khandaker MH, Kong C, Singh B, Xu L, Ochi A, Feldman RD, Pickering JG, Gill BM, et al. (1999). Bacterial superantigens in- duce down-modulation of CC chemokine responsiveness in human, monocytes via an alternative chemokine ligand-independent mechanism. J. Immunol 162, 2299-2307.
39. Sica A, Saccani A, Borsatti A, Power CA, Wells TN, Luini W, Polentarutti N, Sozzani S, and Mantovani A (1997). Bacterial lipopolysaccharide rapidly in- hibits expression of C-C chemokine receptors in human monocytes. J. Exp Med 185, 969-974.
40. Kim HK, Kim JE, Chung J, Han KS, and Cho HI (2007). Surface expression ofneutroph.il CXCR4 is down-modulated by bacterial endotoxin. IntJHematol 85, 390-396.
41. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, and Bachelerie F (2005). The chemokine SDF-I/CXCLl 2 binds to and signals through, the orphan receptor RDCl in T lymphocytes. J. Biol Chem 280, 35760-35766.
42. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen. M, and Alon R (2008). A crosstalk between intra- cellular CXC. R7 and. CXC. R4 involved in rapid CXCL12-triggered integrin ac- tivation but not in chemokine-triggered motility of human T lymphocytes and CD34* cells. J. Leukoc Biol 84, 1130-1140.
43. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, Woehl B, Leung H, Groom J, Batten M, et al. (2007). Disrupted cardiac de- velopment but normal hematopoiesis in mice deficient in the second CXCLl 2 /SDF-I receptor, CXCR7. Proc Natl Acad Sei USA 104, 14759-14764.
44. Chambers AF, Groom AC, and MacDonald IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
45. Finn RS (2008). Targeting Src in breast cancer. Ann Oncol 19, 1379-1386.
46. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR Estey EH, et al. (2008). Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 2008 October 27. [Epub ahead of print].
47. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim. J, Suzuki Y, Minoguchi S, Tamamura H, Waki M, Matsumoto A, et al. (1999). Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. /VW 73, 7489-7496.
48. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ram.an. an S, Mochizuki K, Baba M, Fujii N, and Nakashima H (1999). T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol 73, 1719-1723.
49. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, et al. (1998). A low-molecular-weight inhibi- tor against the chemokine receptor CXCR4: a strong anti-HIV peptide Tl 40. Biochem Biophys Res Commun 253, 877-882.
50. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, et al. (2004). Safety, pharmaco- kinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-I infection. J Acguir Immune Defic Syndr 37, 1253-1262.
51. Hatse S, Princen K, De CE, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, Skerlj RT, Bridger GJ, and Schols D (2005). AMD3465, a monomacrocydic CXCR4 antagonist and potent HIVentry inhibitor. Biochem Pharmacol70, 752-761.